TrialJournal of inherited metabolic disease2004

Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.

D Elstein et al.PubMed ↗Publisher ↗

No numbers read from the abstract.